Puma Biotechnology (PBYI) Cash from Operations (2010 - 2026)
Puma Biotechnology's (PBYI) quarterly Cash from Operations came in at 15416000.0 in Q1 2026, up 326.8% YoY from 3612000.0 in Q1 2025, and up 6.91% on a QoQ basis from 14419000.0 in Q4 2025.
Puma Biotechnology (PBYI) Cash from Operations (2010 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 17 years of Cash from Operations data on file, last reported at 15416000.0 in Q1 2026.
- Quarterly Cash from Operations rose 326.8% year-over-year to 15416000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53606000.0 (up 71.35% YoY) and the FY2025 annual result came in at 41802000.0, up 7.41% from the prior year.
- Cash from Operations grew to 15416000.0 in Q1 2026, from 14419000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 17259000.0 in Q3 2022 to a low of 26895000.0 in Q1 2022.
- A 5-year average of 6312823.53 and a median of 10455000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 18648.65% — and 2025, when it jumped 1271.18%.
- Tracing PBYI's Cash from Operations over 5 years: stood at 7683000.0 in 2022, then surged by 36.08% to 10455000.0 in 2023, then jumped by 49.28% to 15607000.0 in 2024, then decreased by 7.61% to 14419000.0 in 2025, then increased by 6.91% to 15416000.0 in 2026.
- The last three Cash from Operations figures came in at 15416000.0 (Q1 2026), 14419000.0 (Q4 2025), and 9689000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 1.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.62 Mn |
| Jun 30, 2026 | 1.62 Mn |
| Mar 31, 2026 | 15.42 Mn |
| Mar 31, 2026 | 15.42 Mn |
| Dec 31, 2025 | 14.42 Mn |
| Dec 31, 2025 | 14.42 Mn |
| Sep 30, 2025 | 9.69 Mn |
| Sep 30, 2025 | 9.69 Mn |
| Jun 30, 2025 | 14.08 Mn |
| Jun 30, 2025 | 14.08 Mn |
| Mar 31, 2025 | 3.61 Mn |
| Mar 31, 2025 | 3.61 Mn |
| Dec 31, 2024 | 15.61 Mn |
| Dec 31, 2024 | 15.61 Mn |
| Sep 30, 2024 | 11.04 Mn |
| Sep 30, 2024 | 11.04 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 11.25 Mn |
| Mar 31, 2024 | 11.25 Mn |